期刊
HEPATOLOGY
卷 49, 期 5, 页码 S56-S60出版社
WILEY
DOI: 10.1002/hep.22962
关键词
-
资金
- NIAID NIH HHS [R21 AI076834, 1R21AI076834-01] Funding Source: Medline
- NIDDK NIH HHS [U01 DK082871, U01 DK082871-01, N01-DK-9-2324, 1U01 DK082871-01] Funding Source: Medline
Chronic infection with the hepatitis B virus has been linked epidemiologically to the development of hepatocellular carcinoma for more than 30 years. Although the mechanisms by which chronic hepatitis B viral infection results in hepatocellular carcinoma are unclear, there is good evidence that the virus itself exerts a direct hepatocarcinogenic effect, and this has implications for prevention. First, programs of universal infant vaccination have been shown to be effective in reducing the rate of hepatocellular carcinoma among children. This benefit should be translated into adulthood among vaccine recipients. Second, it has been suggested that antiviral therapy against hepatitis B may reduce the risk of hepatocellular carcinoma. Antiviral therapy against hepatitis B is effective in causing prolonged lowering of serum levels of hepatitis B virus DNA. There are emerging data showing that prolonged antiviral therapy may reduce the risk of hepatocellular carcinoma among certain patients with chronic hepatitis B. (HEPATOLOGY 2009;49:S56-S60.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据